This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://linked.opendata.cz/resource/drugbank/drug/DB02034/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB02034/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB02034/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB02034/identifier/pdb/
n9http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB02034/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB02034/identifier/pubchem-substance/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/drug/DB02034/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB02034
rdf:type
n3:Drug
n3:description
An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity. [PubChem]
n3:group
experimental
owl:sameAs
n9:DB02034 n10:DB02034
dcterms:title
Swainsonine
adms:identifier
n7:Swainsonine n11:10975968 n12:46506581 n13:C10173 n14:SWA n15:5170 n16:DB02034
n3:synthesisReference
William H. Pearson, Erik J. Hembre, "Method for preparing swainsonine." U.S. Patent US5919952, issued December, 1986.
n3:IUPAC-Name
n4:271B5E7E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E84-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E83-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E80-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E81-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E82-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E7C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E7D-363D-11E5-9242-09173F13E4C5 n4:271B5E7A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E7B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5E8A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E8B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E85-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E86-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E88-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E87-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E89-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
72741-87-8
n3:Bioavailability
n4:271B5E90-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E92-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E93-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5E94-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E8F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E8E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E91-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E7F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5E8C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E8D-363D-11E5-9242-09173F13E4C5